Anna Hockaday

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Graham Jackson, Faith E. Davies, Charlotte Pawlyn et al. · The Lancet Oncology · 2018 · 340 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Talha Munir, David A. Cairns, Adrian Bloor et al. · New England Journal of Medicine · 2023 · 155 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Gordon Cook, A. John Ashcroft, David A. Cairns et al. · The Lancet Haematology · 2016 · 149 citations

Medicine, Hematology, Oncology +14

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

Gordon Cook, Kara‐Louise Royle, Charlotte Pawlyn et al. · The Lancet Haematology · 2019 · 109 citations · Full text

Public Health, Biostatistics, Risk Assessment +13

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor et al. · The Lancet Oncology · 2023 · 106 citations · Full text

Medicine, Immunology, Pharmacotherapy +14